Status:
UNKNOWN
Ablation as First Line Treatment in Paroxysmal Atrial Fibrillation
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Paroxysmal Atrial Fibrillation
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether catheter ablation is more effective than antiarrhythmic drugs in the early stages of paroxysmal atrial fibrillation. In all the patients a subcutaneou...
Eligibility Criteria
Inclusion
- Age between 18 and 65
- At least three episodes of paroxysmal atrial fibrillation documented on an electrocardiogram or event recording during the last three years
- Never taken antiarrhythmic drugs or at most a pill in the pocket approach
- Willingness, ability and commitment to participate in baseline and follow-up evaluations
Exclusion
- Paroxysmal AF for more than three years
- An episode of atrial fibrillation that lasted more than seven days within the past six months
- Persistent/permanent atrial fibrillation
- Atrial fibrillation from reversible cause (i.e. surgery, hyperthyroidism, pericarditis)
- Documented atrial flutter
- Structural heart disease of clinical significance including:
- Cardiac surgery within six months of screening
- Unstable symptoms of congestive heart failure (CHF) including NYHA Class III or IV CHF at screening and/or ejection fraction \<30% as measured by echocardiography or catheterization
- Unstable angina
- Myocardial infarction within six months of screening
- Surgically corrected atrial septal defect with a patch or closure device
- LA size \> 40mm
- Any prior ablation of the pulmonary veins
- Enrollment in any other ongoing protocol
- Untreatable allergy to contrast media
- Pregnancy
- Any contraindication to cardiac catheterization
- Prosthetic mitral heart valve
- Poor general health that, in the opinion of the Investigator, will not allow the patient to be a good study candidate (i.e. other disease processes, mental capacity, etc.)
- Contraindication to coumadin or heparin
- History of pulmonary embolus or stroke within one year of screening
- Acute pulmonary edema
- Atrial clot on TEE regardless of the patient's anticoagulation medication status
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2016
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01466842
Start Date
January 1 2012
End Date
January 1 2016
Last Update
November 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University Medical Centre
Maastricht, Netherlands, 6229 HX